Value
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 0.0 |
| P/S | 9.5 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 6.2 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 20.9x
- ▸PEG: 0.08
PRVA · Why this verdict
Why Privia Health Group (PRVA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Privia Health Group is growing revenue at 26% annually with strong analyst conviction (8.9/10 rating, 36% upside target) and exceptional free cash flow conversion of 508%, but a quality score of 3.5 below the minimum threshold and the recent Q1 2026 earnings miss are key risks to monitor.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Privia Health grew revenue by 26% year over year and the business achieved a Piotroski F-Score of 7/9, reflecting broad improvement across profitability, leverage, and operational efficiency metrics for this healthcare IT platform. Growth breakdown | Annual revenue growth remains above 15% in the next reported fiscal year, demonstrating that the physician enablement platform continues to scale at above-average industry rates. | →Stable |
| CounterHealthcare IT platform revenue growth can be lumpy depending on provider network onboarding timing, and 26% may front-load benefits that slow in the following year. | ||
Free cash flow is 508% of reported net income, indicating that accounting earnings significantly understate actual cash generation, and this gap likely reflects amortization of acquired intangibles that suppress GAAP net income without representing economic cost. Quality breakdown | Free cash flow conversion remains above 200% of net income in the next annual period, confirming the structural cash generation advantage. | →Stable |
| CounterFCF-to-net-income ratios this high often normalize as intangible amortization tails off or as growth capex ramps, making the premium relative to GAAP earnings temporary. | ||
Analysts rate Privia at 8.9 out of 10 and see 36% upside to a consensus target, with the current analyst target implying a price of $28.28 versus the current $23.02, making this one of the higher analyst conviction setups in the healthcare information services group. Sentiment | Analyst price target is maintained or raised and price appreciates toward $28 within 12 months, capturing at least half of the implied analyst upside. | ↑Improving |
| CounterHigh analyst ratings and upside estimates in healthcare IT have frequently been disappointed by reimbursement pressure, regulatory changes, or slower-than-expected physician adoption. | ||
The quality score of 3.5 falls below the minimum 4.0 threshold, and the most recent quarter ended May 2026 showed a -24% earnings miss, introducing uncertainty about whether the strong historical beat record (3 of 4 quarters) can be maintained. Earnings | The next quarterly earnings report delivers a positive surprise above 10%, and quality metrics improve to above 4.0 within 2 reporting cycles. | ↓Deteriorating |
| CounterA single miss in an otherwise strong beat track record could be noise, especially if the Q1 miss was driven by a one-time cost item rather than structural deterioration. | ||
Privia Health grew revenue by 26% year over year and the business achieved a Piotroski F-Score of 7/9, reflecting broad improvement across profitability, leverage, and operational efficiency metrics for this healthcare IT platform.
→StableGrowth breakdown
- Expectation
- Annual revenue growth remains above 15% in the next reported fiscal year, demonstrating that the physician enablement platform continues to scale at above-average industry rates.
CounterHealthcare IT platform revenue growth can be lumpy depending on provider network onboarding timing, and 26% may front-load benefits that slow in the following year.
Free cash flow is 508% of reported net income, indicating that accounting earnings significantly understate actual cash generation, and this gap likely reflects amortization of acquired intangibles that suppress GAAP net income without representing economic cost.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 200% of net income in the next annual period, confirming the structural cash generation advantage.
CounterFCF-to-net-income ratios this high often normalize as intangible amortization tails off or as growth capex ramps, making the premium relative to GAAP earnings temporary.
Analysts rate Privia at 8.9 out of 10 and see 36% upside to a consensus target, with the current analyst target implying a price of $28.28 versus the current $23.02, making this one of the higher analyst conviction setups in the healthcare information services group.
↑ImprovingSentiment
- Expectation
- Analyst price target is maintained or raised and price appreciates toward $28 within 12 months, capturing at least half of the implied analyst upside.
CounterHigh analyst ratings and upside estimates in healthcare IT have frequently been disappointed by reimbursement pressure, regulatory changes, or slower-than-expected physician adoption.
The quality score of 3.5 falls below the minimum 4.0 threshold, and the most recent quarter ended May 2026 showed a -24% earnings miss, introducing uncertainty about whether the strong historical beat record (3 of 4 quarters) can be maintained.
↓DeterioratingEarnings
- Expectation
- The next quarterly earnings report delivers a positive surprise above 10%, and quality metrics improve to above 4.0 within 2 reporting cycles.
CounterA single miss in an otherwise strong beat track record could be noise, especially if the Q1 miss was driven by a one-time cost item rather than structural deterioration.
Per-dimension breakdown
Quality
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.4 |
| ROA | 1.4 |
| Gross margin | 0.0 |
| Op margin | 0.7 |
| Net margin | 0.6 |
| Current ratio | 5.8 |
| FCF quality | 10.0 |
| Moat | 6.4 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 340% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
Growth
8.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.8 |
| EPS growth | 10.0 |
- ▸Strong growth: 21% YoY
Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 8.3 |
- ▸Capitulation risk (RSI 22, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.2%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.7 |
| Analyst rating | 8.8 |
| Price target | 9.2 |
- ▸LLM news sentiment: +0.33 (n=3)
- ▸Analyst upside: 41%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $8,282,858 (0.289% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.3 |
| quality rank | 5.0 |
| growth rank | 6.8 |
- ▸Conservative debt levels
Technical
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.8 |
| support resistance | 7.0 |
| 52w position | 5.6 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.8 |
| days to cover | 7.8 |
| volatility | 0.0 |
| put call | 8.8 |
| implied vol | 0.0 |
| beta | 7.6 |
| debt equity | 10.0 |
- ▸High IV: 84%
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 4.7 |
| news activity | 7.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- ASYMMETRY:2.2>=1.5
- 8K:CLEAN
- EARNINGS_PROXIMITY:86d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.9<4.5
Warning (1)
- INSIDER:0.29%=MODERATE
Reward-to-Risk
2.17
Upside
+26.6%
Downside
12.2%
Sizing output
AVOID
SetupOversold Bounce — Oversold RSI 22, near Bollinger lower, volume surge
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.9B<$5B
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.9<4.5 outcome against Growth at 8.9 and asymmetric R:R of 2.17.
The strongest dimensions are Growth at 8.9, Sentiment at 8.2, and Technical at 7.1; the weakest are Momentum at 2.9, Quality at 3.9, and Catalyst at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 2.17 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth Physician Platform
Trip ifAnnual revenue growth falls below 10% in the next reported fiscal year.
- P2Exceptional Fcf Conversion
Trip ifFree cash flow conversion drops below 100% of net income in any reported annual period.
- P3Analyst Conviction 36pct Upside
Trip ifAnalyst consensus price target falls below $22, reducing implied upside to less than 5% from current levels.
- P4Quality Floor Breach Recent Miss
Trip ifEarnings miss rate rises to 3 or more misses in the next 4 quarters, with average negative surprise below -15%.